Günther, René

[["dc.bibliographiccitation.artnumber","304"],["dc.bibliographiccitation.journal","Frontiers in Neuroscience"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Günther, R."],["dc.contributor.author","Saal, K.-A."],["dc.contributor.author","Suhr, M."],["dc.contributor.author","Scheer, D."],["dc.contributor.author","Koch, J. C."],["dc.contributor.author","Bähr, M."],["dc.contributor.author","Lingor, P."],["dc.contributor.author","Tönges, L."],["dc.date.accessioned","2017-09-07T11:45:27Z"],["dc.date.available","2017-09-07T11:45:27Z"],["dc.date.issued","2014"],["dc.description.abstract","Disease progression in amyotrophic lateral sclerosis (ALS) is characterized by degeneration of motoneurons and their axons which results in a progressive muscle weakness and ultimately death from respiratory failure. The only approved drug, riluzole, lacks clinical efficacy so that more potent treatment options are needed. We have identified rho kinase (ROCK) as a target, which can be manipulated to beneficially influence disease progression in models of ALS. Here, we examined the therapeutic potential of the ROCK inhibitor Y-27632 in both an in vitro and in an in vivo paradigm of motoneuron disease. Application of Y-27632 to primary motoneurons in vitro increased survival and promoted neunte outgrowth. In vivo, SOD1G93A mice were orally treated with 2 or 30 mg/kg body weight of Y-27632. The 2 mg/kg group did not benefit from Y-27632 treatment, whereas treatment with 30 mg/kg resulted in improved motor function in male mice. Female mice showed only limited improvement and overall survival was not modified in both 2 and 30 mg/kg Y-27632 groups. In conclusion, we provide evidence that inhibition of ROCK by Y-27632 is neuroprotective in vitro but has limited beneficial effects in vivo being restricted to male mice. Therefore, the evaluation of ROCK inhibitors in preclinical models of ALS should always take gender differences into account."],["dc.format.extent","9"],["dc.identifier.doi","10.3389/fnins.2014.00304"],["dc.identifier.gro","3142033"],["dc.identifier.isi","000346516800001"],["dc.identifier.pmid","25339858"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11029"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/3801"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1662-453X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","The rho kinase inhibitor Y-27632 improves motor performance in male SOD1(G93A) mice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","175628641984605"],["dc.bibliographiccitation.journal","Therapeutic Advances in Neurological Disorders"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Wurster, Claudia D."],["dc.contributor.author","Günther, René"],["dc.contributor.author","Steinacker, Petra"],["dc.contributor.author","Dreyhaupt, Jens"],["dc.contributor.author","Wollinsky, Kurt"],["dc.contributor.author","Uzelac, Zeljko"],["dc.contributor.author","Witzel, Simon"],["dc.contributor.author","Kocak, Tugrul"],["dc.contributor.author","Winter, Benedikt"],["dc.contributor.author","Koch, Jan C."],["dc.contributor.author","Lingor, Paul"],["dc.contributor.author","Petri, Susanne"],["dc.contributor.author","Ludolph, Albert C."],["dc.contributor.author","Hermann, Andreas"],["dc.contributor.author","Otto, Markus"],["dc.date.accessioned","2020-12-10T18:38:37Z"],["dc.date.available","2020-12-10T18:38:37Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1177/1756286419846058"],["dc.identifier.eissn","1756-2864"],["dc.identifier.issn","1756-2864"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16746"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77390"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","372"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Brain Sciences"],["dc.bibliographiccitation.volume","11"],["dc.contributor.affiliation","Peseschkian, Tara; \t\t \r\n\t\t Department of Neurology, Hannover Medical School, 30625 Hannover, Germany, Peseschkian.Tara@mh-hannover.de"],["dc.contributor.affiliation","Cordts, Isabell; \t\t \r\n\t\t Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany, isabell.cordts@tum.de"],["dc.contributor.affiliation","Günther, René; \t\t \r\n\t\t Department of Neurology, University Hospital Carl Gustav Carus, 01307 Dresden, Germany, Rene.Guenther@uniklinikum-dresden.de\t\t \r\n\t\t German Center for Neurodegenerative Diseases (DZNE), 01307 Dresden, Germany, Rene.Guenther@uniklinikum-dresden.de"],["dc.contributor.affiliation","Stolte, Benjamin; \t\t \r\n\t\t Department of Neurology, University Medicine Essen, 45147 Essen, Germany, benjamin.stolte@uk-essen.de"],["dc.contributor.affiliation","Zeller, Daniel; \t\t \r\n\t\t Department of Neurology, University of Würzburg, 97080 Würzburg, Germany, Zeller_D@ukw.de"],["dc.contributor.affiliation","Schröter, Carsten; \t\t \r\n\t\t Hoher Meißner Clinic, Neurology, 37242 Bad Sooden-Allendorf, Germany, Schroeter@reha-klinik.de"],["dc.contributor.affiliation","Weyen, Ute; \t\t \r\n\t\t Department of Neurology, Ruhr-University Bochum, BG-Kliniken Bergmannsheil, 44789 Bochum, Germany, ute.weyen@bergmannsheil.de"],["dc.contributor.affiliation","Regensburger, Martin; \t\t \r\n\t\t Department of Molecular Neurology, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany, Martin.Regensburger@uk-erlangen.de"],["dc.contributor.affiliation","Wolf, Joachim; \t\t \r\n\t\t Department of Neurology, Diakonissen Hospital Mannheim, 68163 Mannheim, Germany, j.wolf@diako-mannheim.de"],["dc.contributor.affiliation","Schneider, Ilka; \t\t \r\n\t\t Department of Neurology, Martin-Luther University Halle/Saale, 06120 Halle, Germany, Ilka.Schneider@sanktgeorg.de\t\t \r\n\t\t Department of Neurology, Klinikum Sankt Georg, 04129 Leipzig, Germany, Ilka.Schneider@sanktgeorg.de"],["dc.contributor.affiliation","Hermann, Andreas; \t\t \r\n\t\t Translational Neurodegeneration Section “Albrecht-Kossel”, Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany, Andreas.Hermann@med.uni-rostock.de\t\t \r\n\t\t German Center for Neurodegenerative Diseases Rostock/Greifswald, 18147 Rostock, Germany, Andreas.Hermann@med.uni-rostock.de"],["dc.contributor.affiliation","Metelmann, Moritz; \t\t \r\n\t\t Department of Neurology, University Hospital Leipzig, 04103 Leipzig, Germany, Moritz.Metelmann@medizin.uni-leipzig.de"],["dc.contributor.affiliation","Kohl, Zacharias; \t\t \r\n\t\t Department of Neurology, University of Regensburg, 93053 Regensburg, Germany, zacharias.kohl@klinik.uni-regensburg.de"],["dc.contributor.affiliation","Linker, Ralf A.; \t\t \r\n\t\t Department of Neurology, University of Regensburg, 93053 Regensburg, Germany, Ralf.Linker@klinik.uni-regensburg.de"],["dc.contributor.affiliation","Koch, Jan Christoph; \t\t \r\n\t\t Department of Neurology, University Medicine Göttingen, 37075 Göttingen, Germany, jkoch@med.uni-goettingen.de"],["dc.contributor.affiliation","Büchner, Boriana; \t\t \r\n\t\t Friedrich-Baur Institute, Department of Neurology, University Hospital, Ludwig Maximilian University of Munich, 80336 Munich, Germany, Boriana.Buechner@med.uni-muenchen.de"],["dc.contributor.affiliation","Weiland, Ulrike; \t\t \r\n\t\t Department of Neurology, University of Ulm, 89081 Ulm, Germany, Ulrike.Weiland@uniklinik-ulm.de"],["dc.contributor.affiliation","Schönfelder, Erik; \t\t \r\n\t\t Department of Neurology, Hannover Medical School, 30625 Hannover, Germany, Erik.Schoenfelder@stud.mh-hannover.de"],["dc.contributor.affiliation","Heinrich, Felix; \t\t \r\n\t\t Department of Neurology, Hannover Medical School, 30625 Hannover, Germany, Felix.Heinrich@stud.mh-hannover.de"],["dc.contributor.affiliation","Osmanovic, Alma; \t\t \r\n\t\t Department of Neurology, Hannover Medical School, 30625 Hannover, Germany, dr.almaosmanovic@gmail.com"],["dc.contributor.affiliation","Klopstock, Thomas; \t\t \r\n\t\t Friedrich-Baur Institute, Department of Neurology, University Hospital, Ludwig Maximilian University of Munich, 80336 Munich, Germany, Thomas.Klopstock@med.uni-muenchen.de\t\t \r\n\t\t Munich Cluster for Systems Neurology (SyNergy), 80336 Munich, Germany, Thomas.Klopstock@med.uni-muenchen.de\t\t \r\n\t\t German Center for Neurodegenerative Diseases (DZNE), 80336 Munich, Germany, Thomas.Klopstock@med.uni-muenchen.de"],["dc.contributor.affiliation","Dorst, Johannes; \t\t \r\n\t\t Department of Neurology, University of Ulm, 89081 Ulm, Germany, johannes.dorst@rku.de"],["dc.contributor.affiliation","Ludolph, Albert C.; \t\t \r\n\t\t Department of Neurology, University of Ulm, 89081 Ulm, Germany, albert.ludolph@rku.de\t\t \r\n\t\t German Center for Neurodegenerative Diseases (DZNE), 89081 Ulm, Germany, albert.ludolph@rku.de"],["dc.contributor.affiliation","Boentert, Matthias; \t\t \r\n\t\t Department of Neurology with the Institute of Translational Neurology, University Hospital Münster, 48149 Münster, Germany, Matthias.Boentert@ukmuenster.de\t\t \r\n\t\t Department of Medicine, UKM Marienhospital, 48565 Steinfurt, Germany, Matthias.Boentert@ukmuenster.de"],["dc.contributor.affiliation","Hagenacker, Tim; \t\t \r\n\t\t Department of Neurology, University Medicine Essen, 45147 Essen, Germany, tim.hagenacker@uk-essen.de"],["dc.contributor.affiliation","Deschauer, Marcus; \t\t \r\n\t\t Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany, marcus.deschauer@mri.tum.de"],["dc.contributor.affiliation","Lingor, Paul; \t\t \r\n\t\t Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany, paul.lingor@tum.de"],["dc.contributor.affiliation","Petri, Susanne; \t\t \r\n\t\t Department of Neurology, Hannover Medical School, 30625 Hannover, Germany, Petri.Susanne@mh-hannover.de"],["dc.contributor.affiliation","Schreiber-Katz, Olivia; \t\t \r\n\t\t Department of Neurology, Hannover Medical School, 30625 Hannover, Germany, Schreiber-Katz.Olivia@mh-hannover.de"],["dc.contributor.author","Peseschkian, Tara"],["dc.contributor.author","Cordts, Isabell"],["dc.contributor.author","Günther, René"],["dc.contributor.author","Stolte, Benjamin"],["dc.contributor.author","Zeller, Daniel"],["dc.contributor.author","Schröter, Carsten"],["dc.contributor.author","Weyen, Ute"],["dc.contributor.author","Regensburger, Martin"],["dc.contributor.author","Wolf, Joachim"],["dc.contributor.author","Schneider, Ilka"],["dc.contributor.author","Hermann, Andreas"],["dc.contributor.author","Metelmann, Moritz"],["dc.contributor.author","Kohl, Zacharias"],["dc.contributor.author","Linker, Ralf A."],["dc.contributor.author","Koch, Jan Christoph"],["dc.contributor.author","Büchner, Boriana"],["dc.contributor.author","Weiland, Ulrike"],["dc.contributor.author","Schönfelder, Erik"],["dc.contributor.author","Heinrich, Felix"],["dc.contributor.author","Osmanovic, Alma"],["dc.contributor.author","Klopstock, Thomas"],["dc.contributor.author","Dorst, Johannes"],["dc.contributor.author","Ludolph, Albert C."],["dc.contributor.author","Boentert, Matthias"],["dc.contributor.author","Hagenacker, Tim"],["dc.contributor.author","Deschauer, Marcus"],["dc.contributor.author","Lingor, Paul"],["dc.contributor.author","Petri, Susanne"],["dc.contributor.author","Schreiber-Katz, Olivia"],["dc.date.accessioned","2021-04-14T08:27:57Z"],["dc.date.available","2021-04-14T08:27:57Z"],["dc.date.issued","2021"],["dc.date.updated","2022-02-09T13:21:17Z"],["dc.description.sponsorship","German Neuromuscular Society “Deutsche Gesellschaft fuer Muskelkranke\" e.V."],["dc.identifier.doi","10.3390/brainsci11030372"],["dc.identifier.eissn","2076-3425"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82457"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","MDPI"],["dc.relation.eissn","2076-3425"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Neurology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Günther, René"],["dc.contributor.author","Wurster, Claudia Diana"],["dc.contributor.author","Cordts, Isabell"],["dc.contributor.author","Koch, Jan Christoph"],["dc.contributor.author","Kamm, Christoph"],["dc.contributor.author","Petzold, Daniel"],["dc.contributor.author","Aust, Elisa"],["dc.contributor.author","Deschauer, Marcus"],["dc.contributor.author","Lingor, Paul"],["dc.contributor.author","Ludolph, Albert Christian"],["dc.contributor.author","Hermann, Andreas"],["dc.date.accessioned","2020-12-10T18:44:33Z"],["dc.date.available","2020-12-10T18:44:33Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.3389/fneur.2019.01098"],["dc.identifier.eissn","1664-2295"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16912"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78498"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","748"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Brain Sciences"],["dc.bibliographiccitation.volume","11"],["dc.contributor.affiliation","Schischlevskij, Pavel; \t\t \r\n\t\t Department of Neurology, Hannover Medical School, 30625 Hannover, Germany, Schischlevskij.Pavel@mh-hannover.de"],["dc.contributor.affiliation","Cordts, Isabell; \t\t \r\n\t\t Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany, isabell.cordts@tum.de"],["dc.contributor.affiliation","Günther, René; \t\t \r\n\t\t Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany, Rene.Guenther@uniklinikum-dresden.de\t\t \r\n\t\t German Center for Neurodegenerative Diseases (DZNE), 01307 Dresden, Germany, Rene.Guenther@uniklinikum-dresden.de"],["dc.contributor.affiliation","Stolte, Benjamin; \t\t \r\n\t\t Department of Neurology, University Medicine Essen, 45147 Essen, Germany, benjamin.stolte@uk-essen.de"],["dc.contributor.affiliation","Zeller, Daniel; \t\t \r\n\t\t Department of Neurology, University of Würzburg, 97080 Würzburg, Germany, Zeller_D@ukw.de"],["dc.contributor.affiliation","Schröter, Carsten; \t\t \r\n\t\t Hoher Meißner Clinic, Neurology, 37242 Bad Sooden-Allendorf, Germany, Schroeter@reha-klinik.de"],["dc.contributor.affiliation","Weyen, Ute; \t\t \r\n\t\t Department of Neurology, Ruhr-University Bochum, BG-Kliniken Bergmannsheil, 44789 Bochum, Germany, ute.weyen@bergmannsheil.de"],["dc.contributor.affiliation","Regensburger, Martin; \t\t \r\n\t\t Department of Molecular Neurology, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany, Martin.Regensburger@uk-erlangen.de"],["dc.contributor.affiliation","Wolf, Joachim; \t\t \r\n\t\t Department of Neurology, Diakonissen Hospital Mannheim, 68163 Mannheim, Germany, j.wolf@diako-mannheim.de"],["dc.contributor.affiliation","Schneider, Ilka; \t\t \r\n\t\t Department of Neurology, Martin-Luther University Halle/Saale, 06120 Halle, Germany, Ilka.Schneider@sanktgeorg.de\t\t \r\n\t\t Department of Neurology, Klinikum Sankt Georg, 04129 Leipzig, Germany, Ilka.Schneider@sanktgeorg.de"],["dc.contributor.affiliation","Hermann, Andreas; \t\t \r\n\t\t Translational Neurodegeneration Section “Albrecht-Kossel”, Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany, Andreas.Hermann@med.uni-rostock.de\t\t \r\n\t\t German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, 18147 Rostock, Germany, Andreas.Hermann@med.uni-rostock.de"],["dc.contributor.affiliation","Metelmann, Moritz; \t\t \r\n\t\t Department of Neurology, University Hospital Leipzig, 04103 Leipzig, Germany, Moritz.Metelmann@medizin.uni-leipzig.de"],["dc.contributor.affiliation","Kohl, Zacharias; \t\t \r\n\t\t Department of Neurology, University of Regensburg, 93053 Regensburg, Germany, zacharias.kohl@klinik.uni-regensburg.de"],["dc.contributor.affiliation","Linker, Ralf A.; \t\t \r\n\t\t Department of Neurology, University of Regensburg, 93053 Regensburg, Germany, Ralf.Linker@klinik.uni-regensburg.de"],["dc.contributor.affiliation","Koch, Jan Christoph; \t\t \r\n\t\t Department of Neurology, University Medicine Göttingen, 37075 Göttingen, Germany, jkoch@med.uni-goettingen.de"],["dc.contributor.affiliation","Stendel, Claudia; \t\t \r\n\t\t Department of Neurology, Friedrich-Baur Institute, University Hospital, Ludwig Maximilian University of Munich, 80336 Munich, Germany, Claudia.Stendel@med.uni-muenchen.de\t\t \r\n\t\t German Center for Neurodegenerative Diseases (DZNE), 80336 Munich, Germany, Claudia.Stendel@med.uni-muenchen.de"],["dc.contributor.affiliation","Müschen, Lars H.; \t\t \r\n\t\t Department of Neurology, Hannover Medical School, 30625 Hannover, Germany, Mueschen.Lars@mh-hannover.de"],["dc.contributor.affiliation","Osmanovic, Alma; \t\t \r\n\t\t Department of Neurology, Hannover Medical School, 30625 Hannover, Germany, dr.almaosmanovic@gmail.com"],["dc.contributor.affiliation","Binz, Camilla; \t\t \r\n\t\t Department of Neurology, Hannover Medical School, 30625 Hannover, Germany, Binz.Camilla@mh-hannover.de"],["dc.contributor.affiliation","Klopstock, Thomas; \t\t \r\n\t\t Department of Neurology, Friedrich-Baur Institute, University Hospital, Ludwig Maximilian University of Munich, 80336 Munich, Germany, Thomas.Klopstock@med.uni-muenchen.de\t\t \r\n\t\t German Center for Neurodegenerative Diseases (DZNE), 80336 Munich, Germany, Thomas.Klopstock@med.uni-muenchen.de\t\t \r\n\t\t Munich Cluster for Systems Neurology (SyNergy), 80336 Munich, Germany, Thomas.Klopstock@med.uni-muenchen.de"],["dc.contributor.affiliation","Dorst, Johannes; \t\t \r\n\t\t Department of Neurology, University of Ulm, 89081 Ulm, Germany, johannes.dorst@rku.de"],["dc.contributor.affiliation","Ludolph, Albert C.; \t\t \r\n\t\t Department of Neurology, University of Ulm, 89081 Ulm, Germany, albert.ludolph@rku.de\t\t \r\n\t\t German Center for Neurodegenerative Diseases (DZNE), 89081 Ulm, Germany, albert.ludolph@rku.de"],["dc.contributor.affiliation","Boentert, Matthias; \t\t \r\n\t\t Department of Neurology, Institute of Translational Neurology, University Hospital Münster, 48149 Münster, Germany, Matthias.Boentert@ukmuenster.de\t\t \r\n\t\t Department of Medicine, UKM Marienhospital, 48565 Steinfurt, Germany, Matthias.Boentert@ukmuenster.de"],["dc.contributor.affiliation","Hagenacker, Tim; \t\t \r\n\t\t Department of Neurology, University Medicine Essen, 45147 Essen, Germany, tim.hagenacker@uk-essen.de"],["dc.contributor.affiliation","Deschauer, Marcus; \t\t \r\n\t\t Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany, marcus.deschauer@mri.tum.de"],["dc.contributor.affiliation","Lingor, Paul; \t\t \r\n\t\t Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany, paul.lingor@tum.de"],["dc.contributor.affiliation","Petri, Susanne; \t\t \r\n\t\t Department of Neurology, Hannover Medical School, 30625 Hannover, Germany, Petri.Susanne@mh-hannover.de"],["dc.contributor.affiliation","Schreiber-Katz, Olivia; \t\t \r\n\t\t Department of Neurology, Hannover Medical School, 30625 Hannover, Germany, dr.schreiber-katz@t-online.de"],["dc.contributor.author","Schischlevskij, Pavel"],["dc.contributor.author","Cordts, Isabell"],["dc.contributor.author","Günther, René"],["dc.contributor.author","Stolte, Benjamin"],["dc.contributor.author","Zeller, Daniel"],["dc.contributor.author","Schröter, Carsten"],["dc.contributor.author","Weyen, Ute"],["dc.contributor.author","Regensburger, Martin"],["dc.contributor.author","Wolf, Joachim"],["dc.contributor.author","Schreiber-Katz, Olivia"],["dc.contributor.author","Koch, Jan Christoph"],["dc.contributor.author","Lingor, Paul"],["dc.date.accessioned","2021-08-12T07:45:51Z"],["dc.date.available","2021-08-12T07:45:51Z"],["dc.date.issued","2021"],["dc.date.updated","2022-02-09T13:20:52Z"],["dc.description.abstract","Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes progressive autonomy loss and need for care. This does not only affect patients themselves, but also the patients’ informal caregivers (CGs) in their health, personal and professional lives. The big efforts of this multi-center study were not only to evaluate the caregivers’ burden and to identify its predictors, but it also should provide a specific understanding of the needs of ALS patients’ CGs and fill the gap of knowledge on their personal and work lives. Using standardized questionnaires, primary data from patients and their main informal CGs (n = 249) were collected. Patients’ functional status and disease severity were evaluated using the Barthel Index, the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and the King’s Stages for ALS. The caregivers’ burden was recorded by the Zarit Burden Interview (ZBI). Comorbid anxiety and depression of caregivers were assessed by the Hospital Anxiety and Depression Scale. Additionally, the EuroQol Five Dimension Five Level Scale evaluated their health-related quality of life. The caregivers’ burden was high (mean ZBI = 26/88, 0 = no burden, ≥24 = highly burdened) and correlated with patients’ functional status (rp = −0.555, p < 0.001, n = 242). It was influenced by the CGs’ own mental health issues due to caregiving (+11.36, 95% CI [6.84; 15.87], p < 0.001), patients’ wheelchair dependency (+9.30, 95% CI [5.94; 12.66], p < 0.001) and was interrelated with the CGs’ depression (rp = 0.627, p < 0.001, n = 234), anxiety (rp = 0.550, p < 0.001, n = 234), and poorer physical condition (rp = −0.362, p < 0.001, n = 237). Moreover, female CGs showed symptoms of anxiety more often, which also correlated with the patients’ impairment in daily routine (rs = −0.280, p < 0.001, n = 169). As increasing disease severity, along with decreasing autonomy, was the main predictor of caregiver burden and showed to create relevant (negative) implications on CGs’ lives, patient care and supportive therapies should address this issue. Moreover, in order to preserve the mental and physical health of the CGs, new concepts of care have to focus on both, on not only patients but also their CGs and gender-associated specific issues. As caregiving in ALS also significantly influences the socioeconomic status by restrictions in CGs’ work lives and income, and the main reported needs being lack of psychological support and a high bureaucracy, the situation of CGs needs more attention. Apart from their own multi-disciplinary medical and psychological care, more support in care and patient management issues is required."],["dc.description.abstract","Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes progressive autonomy loss and need for care. This does not only affect patients themselves, but also the patients’ informal caregivers (CGs) in their health, personal and professional lives. The big efforts of this multi-center study were not only to evaluate the caregivers’ burden and to identify its predictors, but it also should provide a specific understanding of the needs of ALS patients’ CGs and fill the gap of knowledge on their personal and work lives. Using standardized questionnaires, primary data from patients and their main informal CGs (n = 249) were collected. Patients’ functional status and disease severity were evaluated using the Barthel Index, the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and the King’s Stages for ALS. The caregivers’ burden was recorded by the Zarit Burden Interview (ZBI). Comorbid anxiety and depression of caregivers were assessed by the Hospital Anxiety and Depression Scale. Additionally, the EuroQol Five Dimension Five Level Scale evaluated their health-related quality of life. The caregivers’ burden was high (mean ZBI = 26/88, 0 = no burden, ≥24 = highly burdened) and correlated with patients’ functional status (rp = −0.555, p < 0.001, n = 242). It was influenced by the CGs’ own mental health issues due to caregiving (+11.36, 95% CI [6.84; 15.87], p < 0.001), patients’ wheelchair dependency (+9.30, 95% CI [5.94; 12.66], p < 0.001) and was interrelated with the CGs’ depression (rp = 0.627, p < 0.001, n = 234), anxiety (rp = 0.550, p < 0.001, n = 234), and poorer physical condition (rp = −0.362, p < 0.001, n = 237). Moreover, female CGs showed symptoms of anxiety more often, which also correlated with the patients’ impairment in daily routine (rs = −0.280, p < 0.001, n = 169). As increasing disease severity, along with decreasing autonomy, was the main predictor of caregiver burden and showed to create relevant (negative) implications on CGs’ lives, patient care and supportive therapies should address this issue. Moreover, in order to preserve the mental and physical health of the CGs, new concepts of care have to focus on both, on not only patients but also their CGs and gender-associated specific issues. As caregiving in ALS also significantly influences the socioeconomic status by restrictions in CGs’ work lives and income, and the main reported needs being lack of psychological support and a high bureaucracy, the situation of CGs needs more attention. Apart from their own multi-disciplinary medical and psychological care, more support in care and patient management issues is required."],["dc.description.sponsorship","German Neuromuscular Society (Deutsche Gesellschaft fuer Muskelkranke e.V.)"],["dc.identifier.doi","10.3390/brainsci11060748"],["dc.identifier.eissn","2076-3425"],["dc.identifier.pii","brainsci11060748"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88560"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.publisher","MDPI"],["dc.relation.eissn","2076-3425"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","293"],["dc.bibliographiccitation.journal","Frontiers in Neurology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Lingor, Paul"],["dc.contributor.author","Weber, Markus"],["dc.contributor.author","Camu, William"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Neuwirth, Christoph"],["dc.contributor.author","Günther, René"],["dc.contributor.author","Benatar, Michael"],["dc.contributor.author","Kuzma-Kozakiewicz, Magdalena"],["dc.contributor.author","Bidner, Helen"],["dc.contributor.author","Blankenstein, Christiane"],["dc.contributor.author","Frontini, Roberto"],["dc.contributor.author","Ludolph, Albert"],["dc.contributor.author","Koch, Jan C."],["dc.date.accessioned","2019-07-09T11:51:01Z"],["dc.date.available","2019-07-09T11:51:01Z"],["dc.date.issued","2019"],["dc.description.abstract","Objectives: Disease-modifying therapies for amyotrophic lateral sclerosis (ALS) are still not satisfactory. The Rho kinase (ROCK) inhibitor fasudil has demonstrated beneficial effects in cell culture and animal models of ALS. For many years, fasudil has been approved in Japan for the treatment of vasospasm in patients with subarachnoid hemorrhage with a favorable safety profile. Here we describe a clinical trial protocol to repurpose fasudil as a disease-modifying therapy for ALS patients. Methods: ROCK-ALS is a multicenter, double-blind, randomized, placebo-controlled phase IIa trial of fasudil in ALS patients (EudraCT: 2017-003676-31, NCT: 03792490). Safety and tolerability are the primary endpoints. Efficacy is a secondary endpoint and will be assessed by the change in ALSFRS-R, ALSAQ-5, slow vital capacity (SVC), ECAS, and the motor unit number index (MUNIX), as well as survival. Efficacy measures will be assessed before (baseline) and immediately after the infusion therapy as well as on days 90 and 180. Patients will receive a daily dose of either 30 or 60 mg fasudil, or placebo in two intravenous applications for a total of 20 days. Regular assessments of safety will be performed throughout the treatment period, and in the follow-up period until day 180. Additionally, we will collect biological fluids to assess target engagement and evaluate potential biomarkers for disease progression. A total of 120 patients with probable or definite ALS (revised El Escorial criteria) and within 6-18 months of the onset of weakness shall be included in 16 centers in Germany, Switzerland and France. Results and conclusions: The ROCK-ALS trial is a phase IIa trial to evaluate the ROCK-inhibitor fasudil in early-stage ALS-patients that started patient recruitment in 2019."],["dc.identifier.doi","10.3389/fneur.2019.00293"],["dc.identifier.pmid","30972018"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16031"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59859"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Neurology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Wurster, Claudia D."],["dc.contributor.author","Koch, Jan C."],["dc.contributor.author","Cordts, Isabell"],["dc.contributor.author","Dreyhaupt, Jens"],["dc.contributor.author","Otto, Markus"],["dc.contributor.author","Uzelac, Zeljko"],["dc.contributor.author","Witzel, Simon"],["dc.contributor.author","Winter, Benedikt"],["dc.contributor.author","Kocak, Tugrul"],["dc.contributor.author","Schocke, Michael"],["dc.contributor.author","Weydt, Patrick"],["dc.contributor.author","Wollinsky, Kurt"],["dc.contributor.author","Ludolph, Albert C."],["dc.contributor.author","Deschauer, Marcus"],["dc.contributor.author","Lingor, Paul"],["dc.contributor.author","Tumani, Hayrettin"],["dc.contributor.author","Hermann, Andreas"],["dc.contributor.author","Günther, René"],["dc.date.accessioned","2020-12-10T18:44:33Z"],["dc.date.available","2020-12-10T18:44:33Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.3389/fneur.2019.01179"],["dc.identifier.eissn","1664-2295"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16957"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78499"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","17"],["dc.bibliographiccitation.journal","Frontiers in pharmacology"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Günther, René"],["dc.contributor.author","Balck, Alexander"],["dc.contributor.author","Koch, Jan C."],["dc.contributor.author","Nientiedt, Tobias"],["dc.contributor.author","Sereda, Michael"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Lingor, Paul"],["dc.contributor.author","Tönges, Lars"],["dc.date.accessioned","2018-01-08T17:25:43Z"],["dc.date.available","2018-01-08T17:25:43Z"],["dc.date.issued","2017"],["dc.description.abstract","Despite an improved understanding of the genetic background and the pathomechanisms of amyotrophic lateral sclerosis (ALS) no novel disease-modifying therapies have been successfully implemented in clinical routine. Riluzole still remains the only clinically approved substance in human ALS treatment with limited efficacy. We have previously identified pharmacological rho kinase (ROCK) inhibitors as orally applicable substances in SOD1.G93A transgenic ALS mice (SOD1G93A), which are able to extend survival time and improve motor function after presymptomatic treatment. Here, we have evaluated the therapeutic effect of the orally administered ROCK inhibitor Fasudil starting at a symptomatic disease stage, more realistically reflecting the clinical situation. Oral Fasudil treatment was initiated at a symptomatic stage at 80 days of life (d80) with 30 or 100 mg/kg body weight in both female and male mice. While baseline neurological scoring and survival were not influenced, Fasudil significantly improved motor behavior in male mice. Spinal cord pathology of motoneurons (MN) and infiltrating microglial cells (MG) at disease end-stage were not significantly modified. Although treatment after symptom onset was less potent than treatment in asymptomatic animals, our study shows the therapeutic benefits of this well-tolerated substance, which is already in clinical use for other indications."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2017"],["dc.identifier.doi","10.3389/fphar.2017.00017"],["dc.identifier.pmid","28197100"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14268"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/11574"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Rho Kinase Inhibition with Fasudil in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis-Symptomatic Treatment Potential after Disease Onset"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]